disease

(redirected from graft-versus-host disease)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to graft-versus-host disease: cGVHD
References in periodicals archive ?
Itacitinib is currently in clinical studies for the treatment of naive acute graft-versus-host disease and non-small cell lung cancer.
Ruxolitinib is not approved anywhere in the world as treatment for graft-versus-host disease.
Schubert, Maria Elvira Pizzigatti Correa (2008) Oral Graft-Versus-Host Disease.
Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease.
Graft-versus-host disease in lung transplantation: 4 case reports and literature review.
Cyclosporine and methotrexate were given as prophylaxis against graft-versus-host disease.
Obtain an overview of current drug use in HSCT conditioning and in the management of HSCT complications, including graft-versus-host disease
Biopharmaceutical company Alexion Pharmaceuticals (NasdaqGS:ALXN) reported on Wednesday the receipt of the US Food and Drug Administration (FDA) orphan drug designation (ODD) for ALXN1007 for the treatment of acute graft-versus-host disease (GVHD), a severe and life-threatening rare autoimmune disease that can occur as a complication of stem cell or bone marrow transplantation.
The company said it has taken its method of expanding a population of immune privileged stem cells from the human umbilical cord and combined it with the Cytotronics platform to create large quantities of optimized immunoregulatory stem cells that can be used as an allogeneic, off-the-shelf therapy for the treatment of Graft-versus-Host Disease.
Although transplant specialists have been able to reduce its impact, graft-versus-host disease remains a leading cause of death among patients who receive a stem cell transplant from another person, known as an allogeneic transplant.
On the other hand, both studies show that mismatched cord-blood transplants are less apt to spawn acute attacks of graft-versus-host disease than mismatched marrow is.
With the acquisition of Revimmune for transplant rejection, we obtain a product that we believe can improve the percentage of successful transplants, as evidenced by its ability to dramatically reduce the incidence of chronic Graft-Versus-Host Disease (GVHD) in bone marrow transplants.